285 related articles for article (PubMed ID: 31649026)
21. ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG.
Gong C; Liu H; Song R; Zhong T; Lou M; Wang T; Qi H; Shen J; Zhu L; Shao J
Biochim Biophys Acta; 2016 Apr; 1859(4):612-26. PubMed ID: 26921499
[TBL] [Abstract][Full Text] [Related]
22. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
23. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
Sakurikar N; Thompson R; Montano R; Eastman A
Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
[TBL] [Abstract][Full Text] [Related]
24. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
25. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
26. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
[TBL] [Abstract][Full Text] [Related]
27. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
28. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
29. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
Shu Z; Li Z; Huang H; Chen Y; Fan J; Yu L; Wu Z; Tian L; Qi Q; Peng S; Wei C; Xie Z; Li X; Feng Q; Sheng H; Li G; Wei D; Shan C; Chen G
Oncogene; 2020 Aug; 39(35):5721-5733. PubMed ID: 32712628
[TBL] [Abstract][Full Text] [Related]
30. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
[TBL] [Abstract][Full Text] [Related]
31. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells.
Wayne J; Brooks T; Landras A; Massey AJ
FEBS J; 2021 Aug; 288(15):4507-4540. PubMed ID: 33529438
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
Goss KL; Koppenhafer SL; Harmoney KM; Terry WW; Gordon DJ
Oncotarget; 2017 Oct; 8(50):87016-87032. PubMed ID: 29152060
[TBL] [Abstract][Full Text] [Related]
33. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
34. Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress.
Croushore EE; Koppenhafer SL; Goss KL; Geary EL; Gordon DJ
Cancer Res Commun; 2023 Aug; 3(8):1580-1593. PubMed ID: 37599787
[TBL] [Abstract][Full Text] [Related]
35. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
36. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
37. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase.
Buisson R; Boisvert JL; Benes CH; Zou L
Mol Cell; 2015 Sep; 59(6):1011-24. PubMed ID: 26365377
[TBL] [Abstract][Full Text] [Related]
38. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
[TBL] [Abstract][Full Text] [Related]
40. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.
Sturm MJ; Henao-Restrepo JA; Becker S; Proquitté H; Beck JF; Sonnemann J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8605-8617. PubMed ID: 37097390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
